---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018785"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:28:18.190254+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q1 net loss $68.1M, cash $909.8M; guides FY net loss $360-400M

## Summary
- Net loss of $68.1M for Q1 2023 vs $57.6M loss in Q1 2022; R&D expenses $68.9M (up 22% YoY).
- Cash $909.8M as of March 31, 2023, up from $644.9M in Dec 2022, boosted by $345M public offering in March.
- Updated FY 2023 GAAP net loss guidance to $360-$400M; cash runway projected into 2025.
- Appointed Wei Lin, M.D., as CMO; also hired senior VPs for commercial, regulatory, CMC.
- Clinical progress: RMC-6236 data update mid-2023; RMC-6291 preliminary report H2 2023; RMC-9805 first patient dosing mid-2023.

## SEC filing metadata
- accession: 0000950170-23-018785
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017023018785/0000950170-23-018785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017023018785/rvmd-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018785
- JSON: https://secwatch.observer/filing/0000950170-23-018785.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018785.txt

## Key facts
- Earnings Releases
  Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 8, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000095017023018785/0000950170-23-018785-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.